The drug will be sold as Myfembree (relugolix) for the uterine fibroids indication, and is already available to treat prostate cancer under the Orgovyx brand name. Approval for uterine fibroids ...
The two FDA-approved oral GnRH antagonists – AbbVie and Neurocrine Biosciences' Oriahnn (elagolix) and Myovant's Pfizer-partnered Myfembree (relugolix) – are both combined with hormonal drugs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback